- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07297667
GCAR1, una terapia con cellule T del recettore dell'antigene chimerico (CAR) per tumori solidi recidivanti/refrattari che esprimono GPNMB
Uno studio di Fase I su GCAR1, una terapia con cellule T del recettore dell'antigene chimerico (CAR) per partecipanti con tumori solidi selezionati recidivanti/refrattari che esprimono GPNMB
Only enrolling in Canada.
The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
GCAR1 is a type of CAR-T cell therapy that is designed to identify a protein (GPNMB) that is present on the cells of certain types of cancer. Laboratory tests have shown that GCAR1 helps the immune system recognize cancer cells and may help slow down cancer growth.
The purpose of this study is to find out what effects the new treatment, GCAR1 has on certain cancers. This study will test increasing doses of GCAR1 in participants with alveolar soft part sarcoma (ASPS), triple negative breast cancer (TNBC), and renal cell carcinoma (RCC) expressing high levels of the GPNMB protein, to establish recommended doses for further testing.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Mariam Jafri
- Numero di telefono: 613-533-6430
- Email: mjafri@ctg.queensu.ca
Backup dei contatti dello studio
- Nome: Laura Pearce
- Numero di telefono: 613-533-6430
- Email: lpearce@ctg.queensu.ca
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Reclutamento
- Arthur J.E. Child Comprehensive Cancer Centre
-
Contatto:
- Mona Shafey
- Numero di telefono: 403 944-8047
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Reclutamento
- Ottawa Hospital Research Institute
-
Contatto:
- Natasha Kekre
- Numero di telefono: 71064 613 737-8899
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- University Health Network
-
Contatto:
- Abdulazeez Salawu
- Numero di telefono: 416 946-4501
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Reclutamento
- The Research Institute of the McGill University
-
Contatto:
- Ramy Saleh
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Archival tumour specimen must be positive for GPNMB with high expression by immunohistochemistry (central laboratory testing).
-
Histologically and/or cytologically confirmed diagnosis of one of the following tumours that is advanced/ metastatic/ recurrent or unresectable, for which no curative therapy exists.
-
alveolar soft part sarcoma
-
renal cell carcinoma (excluding clear cell)
-
triple negative breast cancer (ER, PR and HER-2 negative as defined by ASCO/CAP criteria)
-
Must have a formalin fixed paraffin embedded tissue block (from primary or metastatic tumour) available and must have provided informed consent for the release of the block.
-
Presence of radiologically documented disease.
-
Measurable disease as defined by RECIST 1.1.
-
ASPS participants ≥ 15 years of age.
-
TNBC and RCC participants ≥ 18 years of age.
-
ECOG performance status of 0 or 1 or Karnofsky or Lansky > 60.
-
Anticipated life expectancy of ≥ 6 months.
-
Must have received prior systemic therapy as shown below;
-
ASPS - completed all systemic therapy available that has been shown to improve survival (unless contraindicated).
-
TNBC
- Progressive disease following at least one line of systemic treatment for metastatic disease which must include an ADC (all participants) and an ICI (participants whose tumours express PD-L1).
- ≤3 lines of treatment for metastatic disease.
- Must have had at least 1 prior line of cytotoxic chemotherapy for breast cancer, in any setting, which must have included an anthracycline and a taxane (unless contraindicated).
-
RCC - must have progressive disease following at least one line of systemic treatment for metastatic disease that must have included an ICI and a VEGFR targeted agent (unless contraindicated).
-
Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior therapies.
-
Adequate washout must be followed per protocol.
-
Previous major surgery is permitted ≥21 days prior to enrollment
-
Prior external beam radiation is permitted ≥28 prior to enrollment. Concurrent radiotherapy is not permitted.
-
Adequate hematologic and biochemical parameters.
-
Consent and assent, when applicable, must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant or their parent/ legal guardian (if applicable) must sign a consent form prior to screening onto the trial to document their willingness to participate.
-
Fit for leukapheresis and has adequate venous access for cell collection.
-
Must be accessible for treatment and follow up at the participating centre for a minimum of 12 months or for as long as is deemed necessary by the treating physician.
-
Participants of childbearing potential must have agreed to use a highly effective contraceptive method.
Exclusion criteria
- Participants on active anticancer therapy for other advanced or metastatic malignancies.
- Concurrent treatment with other anti-cancer therapy
- Prior therapy with a gene therapy product or any adoptive T cell therapy or prior GPNMB targeting therapy.
- Live attenuated vaccination administered within 30 days prior to or planned within 30 days after GCAR1 therapy.
- Primary immunodeficiency or history of severe autoimmune disease (including: Crohn's disease, rheumatoid arthritis, systemic lupus) requiring immunosuppressive agents/ systemic disease modifying agents within 2 years of enrollment.
- Active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the participant to be managed according to the protocol including but not limited to:
- Hepatitis B or C virus (HBV or HCV). For participants with previous HBV or HCV infection who are currently on treatment, they are eligible if they have an undetectable viral load via quantitative PCR and/or nucleic acid testing
- HIV
- Uncontrolled fungal, bacterial, viral or other infection
- Current infection with HTLV
- Tuberculosis
- Syphilis
- West Nile Virus
- Untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction (including cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects) or unstable angina congestive heart failure or myocardial infarction within the previous year.
- Known sensitivity or allergy to fludarabine, cyclophosphamide or any of their components, or to GCAR1 or any of its components.
- Active intracerebral metastases or leptomeningeal disease. Participants who have received definitive treatment, are clinically stable and do not require corticosteroids are eligible to participate in the trial.
- Pregnant or breastfeeding women.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Infusione GCAR1
|
Assigned at enrollment Assigned at enrollment Dose escalation |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy
Lasso di tempo: 3 years
|
(GCAR1) in participants with selected tumours (alveolar soft part sarcoma, renal cell carcinoma (excluding clear cell), triple negative breast cancer) expressing GPNMB |
3 years
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Durata della risposta
Lasso di tempo: 3 anni
|
3 anni
|
|
Numero e gravità degli eventi avversi GCAR1 utilizzando CTCAE v5.0
Lasso di tempo: 3 anni
|
3 anni
|
|
Tasso di risposta complessivo utilizzando RECIST 1.1
Lasso di tempo: 3 anni
|
3 anni
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Mona Shafey, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Malattie della pelle
- Malattie del seno
- Neoplasie urologiche
- Carcinoma
- Neoplasie renali
- Sarcoma
- Neoplasie, Connettivo e Tessuto Molle
- Neoplasie, tessuto muscolare
- Neoplasie mammarie
- Malattie della pelle e del tessuto connettivo
- Carcinoma, cellule renali
- Neoplasie mammarie triplo negativo
- Sarcoma, parte molle alveolare
- Prodotti chimici organici
- Idrocarburi
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Ciclofosfamide
- fludarabina
Altri numeri di identificazione dello studio
- I246
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .